A detailed history of Woodline Partners LP transactions in Exact Sciences Corp stock. As of the latest transaction made, Woodline Partners LP holds 391,455 shares of EXAS stock, worth $22.7 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
391,455
Previous 56,460 593.33%
Holding current value
$22.7 Million
Previous $2.39 Million 1017.57%
% of portfolio
0.24%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$42.43 - $70.83 $14.2 Million - $23.7 Million
334,995 Added 593.33%
391,455 $26.7 Million
Q2 2024

Aug 14, 2024

SELL
$41.33 - $74.26 $5.7 Million - $10.2 Million
-137,814 Reduced 70.94%
56,460 $2.39 Million
Q1 2024

May 15, 2024

BUY
$56.27 - $73.77 $1.79 Million - $2.34 Million
31,730 Added 19.52%
194,274 $13.4 Million
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $4.82 Million - $6.18 Million
-81,553 Reduced 33.41%
162,544 $12 Million
Q3 2023

Nov 14, 2023

SELL
$65.94 - $99.04 $446,150 - $670,104
-6,766 Reduced 2.7%
244,097 $16.7 Million
Q2 2023

Aug 14, 2023

SELL
$62.68 - $95.05 $2.79 Million - $4.23 Million
-44,460 Reduced 15.05%
250,863 $23.6 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $7.83 Million - $11.7 Million
165,926 Added 128.23%
295,323 $20 Million
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $1.06 Million - $1.85 Million
34,765 Added 36.74%
129,397 $6.41 Million
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $3.03 Million - $4.67 Million
94,632 New
94,632 $3.08 Million
Q3 2020

Nov 16, 2020

SELL
$72.92 - $102.01 $2.58 Million - $3.61 Million
-35,432 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$55.75 - $92.75 $1.98 Million - $3.29 Million
35,432 New
35,432 $3.08 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.